Sigma-1 receptor and cardioprotection
Sigma-1受体与心脏保护
基本信息
- 批准号:9091785
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAmyloidAnimal OrganBindingBiochemicalBiochemical GeneticsBioenergeticsBiological AssayCalciumCardiacCardiac MyocytesCardiomyopathiesCessation of lifeComplexCrystallinsDataDiseaseDisease modelEndoplasmic ReticulumGeneticGenetic ModelsHeartHeart DiseasesHeart HypertrophyHeart failureHumanInfectionInjuryInositolIon ChannelIschemiaIschemic Brain InjuryKnock-outKnockout MiceLengthLigand BindingLigandsMediatingMembraneMitochondriaModelingMolecularMolecular ChaperonesMusMutateMutationMyocardial IschemiaMyocardial dysfunctionMyocardiumNeonatalPathologyPhysiologicalProtein ConformationProteinsRNARattusReperfusion InjuryReperfusion TherapyReportingResearch PersonnelRoleSignal TransductionStimulusTestingTransgenic MiceTransgenic Organismsadenoviral-mediatedgain of functiongenetic approachloss of functionmitochondrial dysfunctionmortalitymouse modelmutantnoveloverexpressionprematurepreventprotein aggregateprotein misfoldingreceptorresponsesigma-1 receptortherapeutic targettripolyphosphate
项目摘要
DESCRIPTION (provided by applicant): Project Summary: Sigma-1 receptor (Sigmar1) is a molecular chaperone that is widely expressed in the heart. We showed that Sigmar1 expression is significantly decreased in both human heart failure and in a protein conformation disorder that occurs as a result of cardiomyocyte-specific expression of mutant ¿-B-crystallin (CryABR120G). Despite having potential cardioprotective functions, Sigmar1's role in the heart remains obscure and little is known about Sigmar1's subcellular distribution, functionality, role in heart disease and its downstream signaling effects in the cardiac compartment. To address these limitations, I will use cardiomyocyte-specific Sigmar1 transgenic (Tg) mice and global knockout mice to explore the functionality of Sigmar1 in the heart. The overall objective of this proposal is to uncover the novel molecular functions and mechanisms of Sigmar1 in order to protect the myocardium from both external stimuli and intrinsic insults. Two models of injury will be used: ischemia/reperfusion injury and protein conformation disorder-induced cardiomyopathy. Using both gain-of-function and loss-of-function approaches, I will establish a direct cause-effect relationship to define the involvement and potential protective role of Sigmar1 under pathophysiological conditions in the heart. The central hypothesis is that Sigmar1 activation can be cardioprotective, preventing pathological cardiac remodeling by regulating Ca2+ influx from ER into mitochondria and acting as a chaperone to degrade misfolded proteins. Guided by strong preliminary data, this hypothesis will be tested by pursuing 3 specific aims: 1) To determine the functional role of Sigmar1 in the heart at baseline and in response to heart failure-inducing stimuli. 2) To test the hypothesis that activation of Sigmar1 is sufficient to protect the
heart against protein conformation disorder-induced adverse remodeling and heart failure. 3) To determine if the molecular mechanism underlying Sigmar1- dependent cardioprotection depends upon regulating the calcium influx from ER into mitochondria. These studies will uncover new mechanistic perspectives to therapeutically approach heart failure and will also provide candidates for pharmacologic and genetic targeting.
描述(由申请人提供):项目概述:Sigma-1受体(Sigmar 1)是一种在心脏中广泛表达的分子伴侣。我们发现,Sigmar 1的表达显着降低,在人类心力衰竭和蛋白质构象障碍,发生作为心肌细胞特异性表达的突变体<$-B-晶体蛋白(CryABR 120 G)的结果。尽管具有潜在的心脏保护功能,但Sigmar 1在心脏中的作用仍然不清楚,关于Sigmar 1的亚细胞分布,功能,在心脏疾病中的作用及其在心脏室中的下游信号传导作用知之甚少。为了解决这些局限性,我将使用心肌细胞特异性Sigmar 1转基因(Tg)小鼠和整体敲除小鼠来探索Sigmar 1在心脏中的功能。本研究的总体目标是揭示Sigmar 1的新的分子功能和机制,以保护心肌免受外部刺激和内在损伤。将使用两种损伤模型:缺血/再灌注损伤和蛋白质构象紊乱诱导的心肌病。使用功能获得和功能丧失的方法,我将建立一个直接的因果关系,以确定在心脏病理生理条件下Sigmar 1的参与和潜在的保护作用。核心假设是Sigmar 1激活可以是心脏保护性的,通过调节从ER到线粒体的Ca 2+内流并作为伴侣降解错误折叠的蛋白质来防止病理性心脏重塑。在强有力的初步数据的指导下,该假设将通过追求3个具体目标来检验:1)确定Sigmar 1在基线时和响应心力衰竭诱导刺激时在心脏中的功能作用。2)为了验证Sigmar 1的激活足以保护细胞的假设,
心脏对抗蛋白质构象紊乱引起的不良重构和心力衰竭。3)确定Sigmar 1依赖性心脏保护作用的分子机制是否依赖于调节钙从ER流入线粒体。这些研究将揭示治疗心力衰竭的新机制观点,也将为药理学和遗传靶向提供候选人。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Md. Shenuarin Bhuiyan其他文献
Md. Shenuarin Bhuiyan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Md. Shenuarin Bhuiyan', 18)}}的其他基金
Molecular signaling linking Alzheimer's disease and heart failure
阿尔茨海默病和心力衰竭之间的分子信号传导
- 批准号:
10287798 - 财政年份:2018
- 资助金额:
$ 24.9万 - 项目类别:
相似国自然基金
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
- 批准号:
- 批准年份:2020
- 资助金额:63 万元
- 项目类别:面上项目
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
- 批准号:81870666
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
- 批准号:81601123
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
Beta-amyloid寡聚体特有的抗原表位多肽疫苗的研究
- 批准号:30971012
- 批准年份:2009
- 资助金额:35.0 万元
- 项目类别:面上项目
抗阿兹海默病Beta-Amyloid寡聚物单链可变区抗体的筛选及其动物试验
- 批准号:30570622
- 批准年份:2005
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Elucidating the function of a protective protein in a novel in vitro reconstitution system for disaggregation of ubiquitinated amyloid fibrils
阐明保护蛋白在新型体外重构系统中用于解聚泛素化淀粉样蛋白原纤维的功能
- 批准号:
24K10522 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
新規amyloid-β抑制因子ILEIの減少に伴うアルツハイマー病リスクと分子制御機構の解析
新型β淀粉样蛋白抑制剂ILEI降低相关阿尔茨海默病风险及分子调控机制分析
- 批准号:
23K06805 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Extracting the detrimental effects of amyloid beta oligomer using contextual learning and controlling it with antagonist molecules
使用情境学习提取β淀粉样蛋白寡聚体的有害影响并用拮抗剂分子控制它
- 批准号:
23K06348 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of inhibitors for amyloid peptide aggregation based on peptidomimetics
基于拟肽的淀粉样肽聚集抑制剂的开发
- 批准号:
23K14318 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effect of abnormal beta-amyloid on Ca dynamics in neural cells
异常β-淀粉样蛋白对神经细胞钙动力学的影响
- 批准号:
23K14744 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of novel functions of presenilin in ApoE secretion and brain amyloid removal
阐明早老素在 ApoE 分泌和脑淀粉样蛋白去除中的新功能
- 批准号:
23KF0156 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Project 3: 3-D Molecular Atlas of cerebral amyloid angiopathy in the aging brain with and without co-pathology
项目 3:有或没有共同病理的衰老大脑中脑淀粉样血管病的 3-D 分子图谱
- 批准号:
10555899 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Astrocytic exocytosis of ATP in amyloid pathology and Alzheimer's disease
淀粉样蛋白病理学和阿尔茨海默病中 ATP 的星形细胞胞吐作用
- 批准号:
10722422 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Probing Amyloid Fibril Self-Assembly with Network Hamiltonian Simulations in Explicit Space
用显式空间中的网络哈密顿模拟探测淀粉样蛋白原纤维的自组装
- 批准号:
10715891 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Preservation of brain NAD+ as a novel non-amyloid based therapeutic strategy for Alzheimer’s disease
保留大脑 NAD 作为阿尔茨海默病的一种新型非淀粉样蛋白治疗策略
- 批准号:
10588414 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:














{{item.name}}会员




